# Ruxolitinib for Adult T-Cell Leukemia

> **NCT01712659** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- T Cell Leukemia, Adult
- Leukemia, Adult T-Cell
- T Cell Leukemia, HTLV I Associated

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01712659
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-26
- **Primary completion:** 2021-11-12
- **Final completion:** 2022-01-18
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell malignancy group Lead investigator.
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712659, "Ruxolitinib for Adult T-Cell Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01712659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*